Effect of single hemodialysis session on inflammatory and oxidative stress markers of chronic kidney disease patients
DOI:
https://doi.org/10.55184/ijpas.v75i04.142Keywords:
Chronic kidney disease, pre hemodialysis, post hemodialysis, inflammatory stress, oxidative stress, sterile inflammatory markers.Abstract
Background: Chronic kidney disease (CKD), with its high prevalence, morbidity and mortality, is an important public health problem. The progression of CKD has been shown to result in inflammation and oxidative stress. For CKD hemodialysis (HD) is the most common RRT modality in India. Present study aimed to compare and evaluate the immune modality profile, oxidative marker and biochemical profile of pre and post dialysis chronic kidney disease patients.
Material and method: The study included 40 CKD patients depending on inclusion and exclusion criteria, attending HAHC hospital, HIMSR, New Delhi, which were on hemodialysis. The mean age of the patient was 60±15 yrs. Patients undergoing dialysis thrice in a week for about 4 hrs per session at flow 250-300 ml/min. Inflammatory and oxidative stress markers were assessed pre and post dialysis during any one session of dialysis in chronic kidney disease patients.
Result: There was significant decrease in inflammatory and oxidative stress markers after dialysis. There was also significant decrease in biochemical marker levels post dialysis.
Conclusion: Hence, evident from this study improvement in inflammatory markers and renal function test after dialysis suggests that indeed haemodialysis is the most common and better treatment option for chronic kidney disease patients.
References
REFERENCES:
Abraham G, Varughese S, Thandavan T, Iyengar A, Fernando E, Naqvi SA, Sheriff R, Ur-Rashid H, Gopalakrishnan N,Kafle RK: Chronic kidney disease hotspots in developing countries in South Asia. Clin Kidney J 9: 135–141, 2016.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specifi c all-cause and cause-specifi c mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117–71.
Yan Xie 1, Benjamin Bowe 1, Ali H Mokdad 2, Hong Xian 3, Yan Yan 4, Tingting Li 5, Geetha Maddukuri 6, Cheng-You Tsai 3, Tasheia Floyd :Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018 Sep;94(3):567-581.doi: 10.1016/j.kint.2018.04.011.
White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ 2008; 86: 229–37.
Varughese S, John GT, Alexander S, Deborah MN, Nithya N, Ahamed I, Tamilarasi V, Jacob C: Pre-tertiary hospital care of patients with chronic kidney disease in India. Indian J Med Res 126: 28–33, 2007.
Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011; 80: 1258–70.
Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013 Jan;3(1):19-62.
Black A.P., Cardozo L.F., Mafra D. Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease. Ther. Apher. Dial. 2015;19:436–440. doi: 10.1111/1744-9987.
Popolo A., Adesso S., Pinto A., Autore G., Marzocco S. L-Arginine and its metabolites in kidney and cardiovascular disease. Amino Acids. 2014;46:2271–2286. doi: 10.1007/s00726-014-1825-9.
Marzocco S., Popolo A., Bianco G., Pinto A., Autore G. Pro-apoptotic effect of methylguanidine on hydrogen peroxide-treated rat glioma cell line. Neurochem. Int. 2010;57:518–524. doi: 10.1016/j.neuint.2010.06.016.
Di Iorio B.R., Di Micco L., Marzocco S., De Simone E., De Blasio A., Sirico M.L., Nardone L. UBI Study Group. Very Low-Protein Diet (VLPD) Reduces Metabolic Acidosis in Subjects with Chronic Kidney Disease: The “Nutritional Light Signal” of the Renal Acid Load. Nutrients. 2017;9:69. doi: 10.3390/nu9010069.
Adesso S., Magnus T., Cuzzocrea S., Campolo M., Rissiek B., Paciello O., Autore G., Pinto A., Marzocco S. Indoxyl Sulfate Affects Glial Function Increasing Oxidative Stress and Neuroinflammation in Chronic Kidney Disease: Interaction between Astrocytes and Microglia. Front. Pharmacol. 2017;8:370. doi: 10.3389/fphar.2017.00370.
Kato S., Chmielewski M., Honda H., Pecoits-Filho R., Matsuo S., Yuzawa Y., Tranaeus A., Stenvinkel P., Lindholm B. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 2008;3:1526–1533. doi: 10.2215/CJN.00950208.
Masako K., Kentaro K., Yoshiki S., Kunitoshi I., Yusuke O. Chronic kidney disease, inflammation and cardiovascular disease risk in rheumatoid arthritis. J. Cardiol. 2018;71:277–283.
Popolo A., Autore G., Pinto A., Marzocco S. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic. Res. 2013;47:346–356. doi: 10.3109/10715762.2013.779373.
Qian Q. Inflammation: A Key Contributor to the Genesis and Progression of Chronic Kidney Disease. Contrib. Nephrol. 2017;191:72–83.
Morena M., Cristol J.P., Senécal L., Leray-Moragues H., Krieter D., Canaud B. Oxidative stress inhemodialysis patients: Is NADPH oxidase complex the culprit? Kidney Int. 2002;61:S109–S114.doi: 10.1046/j.1523-1755.61.s80.20.x.
Libetta C., Sepe V., Esposito P., Galli F., Dal Canton A. Oxidative stress and inflammation:Implications in uremia and hemodialysis. Clin. Biochem. 2011;44:1189–1198.doi: 10.1016/j.clinbiochem.2011.06.988.
Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol. Dial. Transplant. 2003;18:1272–1280. doi: 10.1093/ndt/gfg074.
Hasselwander O., Young I.S. Oxidative stress in chronic renal failure. Free Radic. Res. 1998;29:1–11. doi: 10.1080/10715769800300011.
Jha V, Ur-Rashid H, Agarwal SK, Akhtar SF, Kafle RK, Sheriff R; ISN South Asia Regional Board: The state of nephrology in South Asia. Kidney Int 95: 31–37, 2019 10.1016/j.kint.2018.09.001.
Engvall, E. and Perlmann, P. (1972) ‘Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.’, Journal of immunology (Baltimore, Md. : 1950). United States, 109(1), pp. 129–135
Marklund S et al., (1974) ‘Involvement of superoxide anion radicals in the autoxidation of pyrogallol and a convenient assay of superoxide dismutase’ Eur J Biochemistry 47:469-74.
Ohkawa H. et al.,(1979) ‘Assay of lipid peroxide in animal tissue by thiobarbituric acid reaction’ Anal Biochem 95:355.
Hadja Fatima Tbahriti,et al.(2013) ‘Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines’ world J Nephrol, may 6,2(2),31-37.
A.Madhusudhana Rao, et al. (2012) ‘Effect of hemodialysis on plasma myeloperoxidase activity in ESRD patients’ Ind J Clin Biochem (July-Sept 2012) 27(3),253-258.
U. Andersson, H. et al. (2002) ‘HMGB 1 as a DNA- binding cytokines’ J. Leukoe Biol. 72, 1084-1091.
Cross JM, et al. (2001) ‘Dialysis improves endothelial function in humans. Nephrol Dial Transplant , 16, 1823-1829.
Valance P, et al., (1998) ‘Nitric oxide synthesized from L- arginine mediates endothelium dependent dilation in human veins in vivo’ Cardiovasc Res 23(12):1053-1057.
Miric D, et al. (2013) ‘The role of Xanthine oxidase in hemodialysis-induced oxidative injury: Relationship with Nutritional status’ Oxidative Medicine and Cellular Longevity ,1-8.
Demirtas S, et al.(2002) ‘The relation between low-density lipoprotein (LDL) oxidation and hemodialysis with respect to membrane types’ Turk J Med Sci ,32,93-100.
Yalcin AS., et al. (1989). ‘The effect of vitamin E therapy on plasma and erythrocyte lipid peroxidation in chronic hemodialysis patients’ Clin Chem Acta. 185,109-112.
Taccone- Galucci M., et al. (1992) ‘Red blood cell lipid peroxidation in predialysis. chronic renal failure’ Clin Nephrol. 38,48-55.
